Ligand-based approaches to in silico pharmacology.

The development of computational methods that can estimate the various pharmacodynamic and pharmacokinetic parameters that characterise the interaction of drugs with biological systems has been a highly pursued objective over the last 50 years. Among all, methods based on ligand information have emerged as simple, yet highly efficient, approaches to in silico pharmacology. With the recent impact on the identification of new targets for known drugs, they are again the focus of attention in chemical biology and drug discovery.

[1]  R. Solé,et al.  The topology of drug-target interaction networks: implicit dependence on drug properties and target families. , 2009, Molecular bioSystems.

[2]  B Testa,et al.  In silico pharmacology for drug discovery: applications to targets and beyond , 2007, British journal of pharmacology.

[3]  A. Leo,et al.  Chem-bioinformatics: comparative QSAR at the interface between chemistry and biology. , 2002, Chemical reviews.

[4]  Brian K. Shoichet,et al.  Virtual screening of chemical libraries , 2004, Nature.

[5]  Lahana,et al.  How many leads from HTS? , 1999, Drug discovery today.

[6]  Jürgen Bajorath,et al.  Integration of virtual and high-throughput screening , 2002, Nature Reviews Drug Discovery.

[7]  P. Bork,et al.  Drug Target Identification Using Side-Effect Similarity , 2008, Science.

[8]  Roberto Todeschini,et al.  Handbook of Molecular Descriptors , 2002 .

[9]  S. Ekins,et al.  In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling , 2007, British journal of pharmacology.

[10]  Peter Willett,et al.  Similarity-based virtual screening using 2D fingerprints. , 2006, Drug discovery today.

[11]  P Willett,et al.  Similarity-based approaches to virtual screening. , 2003, Biochemical Society transactions.

[12]  E. Jacoby,et al.  Chemogenomics: an emerging strategy for rapid target and drug discovery , 2004, Nature Reviews Genetics.

[13]  Jordi Mestres,et al.  SHED: Shannon Entropy Descriptors from Topological Feature Distributions , 2006, J. Chem. Inf. Model..

[14]  Hans-Joachim Böhm,et al.  A guide to drug discovery: Hit and lead generation: beyond high-throughput screening , 2003, Nature Reviews Drug Discovery.

[15]  Michael J. Keiser,et al.  Predicting new molecular targets for known drugs , 2009, Nature.

[16]  C. Hansch,et al.  p-σ-π Analysis. A Method for the Correlation of Biological Activity and Chemical Structure , 1964 .

[17]  Alka Kurup.  C-QSAR: a database of 18,000 QSARs and associated biological and physical data , 2003, J. Comput. Aided Mol. Des..

[18]  J. Bajorath.  Computational analysis of ligand relationships within target families. , 2008, Current opinion in chemical biology.

[19]  Nikolay P Savchuk,et al.  Exploring the chemogenomic knowledge space with annotated chemical libraries. , 2004, Current opinion in chemical biology.

[20]  Michael J. Keiser,et al.  Relating protein pharmacology by ligand chemistry , 2007, Nature Biotechnology.

[21]  J. Mestres,et al.  A ligand-based approach to mining the chemogenomic space of drugs. , 2008, Combinatorial chemistry & high throughput screening.

[22]  M. Karelson.  Molecular descriptors in QSAR/QSPR , 2000 .

[23]  Thomas Lengauer,et al.  Novel technologies for virtual screening. , 2004, Drug discovery today.

[24]  Walters Wp,et al.  Feature selection in quantitative structure-activity relationships. , 2005 .